117 completed, 19 unknown, 14 terminated, 7 recruiting. 55 Phase 3, 32 Phase 2, 28 Not applicable, 18 Phase 4, 11 Phase 1.
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tenapanor in Maintenance Hemodialysis Patients Tenapanor - Hyperphosphatemia, Maintenance Hemodialysis | Not yet recruiting | Huashan Hospital | 70 | 2026-09-23 | 2026-10-20 | |
| Phosphate in Acute Pancreatitis Sodium Phosphate, Potassium Phosphate - Pancreatitis | Phase 2 | Recruiting | Duke University | 100 | 2026-07-09 | 2026-08-26 |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
| A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China AP301, AP301 Low Dose - Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis | Phase 3 | Recruiting | Alebund Pharmaceuticals | 264 | 2025-06-13 | 2026-01-29 |
| Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism Phosphate Deficiency, Phosphate Overload | Not yet recruiting | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore | 100 | 2025-06-01 | 2025-02-14 | |
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia | Phase 2 | Recruiting | Jemincare | 50 | 2024-12-30 | 2025-02-03 |
| Phosphate Diet Strategies to Lower Blood Phosphate in Dialysis Patients diet education - Hyperphosphataemia, Phosphorus | Not applicable | Completed | Kufa University | 200 | 2024-10-01 | 2025-09-18 |
| Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) - Hyperphosphatemia | Recruiting | LG Chem | 172 | 2023-12-21 | 2026-09-03 | |
| Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients the standard-dose group (4 g/day) - Hyperphosphatemia | Unknown | Kyowa Kirin Korea Co., Ltd. | 600 | 2023-12-21 | 2024-04-29 | |
| Phosphate Urine Excretion in Critically Ill Patients Critically Ill Intensive Care Unit Patients | Active not recruiting | Rabin Medical Center | 205 | 2023-09-11 | 2025-05-28 | |
| Explore the Effectors of The Transtheoretical Model on Nutritional Education in Patients on Hemodialysis multimedia education - End-Stage Kidney Disease, Hyperphosphatemia | Not applicable | Completed | Liu, Liu-Yin | 43 | 2023-07-04 | 2024-05-17 |
| Improving Phosphate Control in Children With CKD Knowledge questionnaire, Focus groups - Chronic Kidney Diseases, Hyperphosphatemia | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 100 | 2023-06-20 | 2023-11-15 | |
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients Cholestyramine Resin 4000 MG [Questran], Calcium Carbonate 500 MG Oral Tablet - Chronic Kidney Diseases, Hemodialysis Complication | Phase 4 | Completed | Ain Shams University | 80 | 2023-03-30 | 2024-08-06 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia doppler ultrasound - AV Fistula | Unknown | Assiut University | 120 | 2022-12-01 | 2022-10-06 | |
| Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease ferric citrate - Hyperphosphatemia Related to Chronic Kidney Disease | Phase 3 | Suspended | Keryx Biopharmaceuticals | 45 | 2022-06-16 | 2026-06-22 |
| mHealth for Phosphorus Management in CKD. mHealth App - Dialysis Related Complication | Not applicable | Unknown | Hospital Universitari de Bellvitge | 50 | 2022-06-01 | 2023-09-22 |
| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo - Anemia, Iron Deficiency, Hyperphosphatemia | Phase 3 | Completed | USRC Kidney Research | 289 | 2022-03-30 | 2025-08-29 |
| Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy - Hyperphosphatemia, Anemia, Iron Deficiency | Phase 4 | Completed | USRC Kidney Research | 214 | 2021-06-29 | 2022-11-07 |
Showing 20 of 164. Sign in to see all of them.
Renal Insufficiency, Chronic (57) · Kidney Failure, Chronic (37) · Renal Insufficiency (18) · Kidney Diseases (10) · Chronic Kidney Disease-Mineral and Bone Disorder (6) · Hyperparathyroidism, Secondary (4) · Anemia, Iron-Deficiency (3) · Cardiovascular Diseases (3) · Hypercalcemia (3) · Hypophosphatemia (3) · Phosphorus Metabolism Disorders (3) · Bone Diseases, Metabolic (2) · Bronchiolitis Obliterans Syndrome (2) · Heart Failure (2)
Nutritional and Metabolic Diseases (164) · Metabolic Diseases (163) · Phosphorus Metabolism Disorders (161) · Female Urogenital Diseases (97) · Female Urogenital Diseases and Pregnancy Complications (97) · Urogenital Diseases (97) · Male Urogenital Diseases (96) · Urologic Diseases (94) · Pathological Conditions, Signs and Symptoms (91) · Pathologic Processes (89) · Chronic Disease (87) · Disease Attributes (87) · Kidney Diseases (86) · Renal Insufficiency (73) · Renal Insufficiency, Chronic (29)
Sevelamer (37) · lanthanum carbonate (21) · ferric citrate (16) · calcium acetate (10) · Calcium Carbonate (9) · cholebine (9) · tenapanor (8) · sucroferric oxyhydroxide (5) · iron-magnesium hydroxycarbonate (4) · Educational Status (3) · Niacinamide (3) · Nutrition Assessment (3) · bixalomer (3) · Niacin (2) · Population Groups (2)
Bayer (10) · Tanabe Pharma Corporation (10) · Astellas Pharma Inc (8) · Kyowa Kirin Co., Ltd. (7) · Ardelyx (6) · Genzyme, a Sanofi Company (6) · Keryx Biopharmaceuticals (6) · Kissei Pharmaceutical Co., Ltd. (5) · Ineos Healthcare Limited (4) · Shire (4) · Alebund Pharmaceuticals (3) · Assiut University (3) · Denver Nephrologists, P.C. (3) · Fresenius Medical Care North America (3) · Panion & BF Biotech Inc. (3)
United States (55) · Japan (34) · Germany (18) · United Kingdom (18) · China (17) · France (13) · Italy (13) · Poland (9) · Spain (9) · Australia (6) · Canada (6) · Hungary (6) · Puerto Rico (6) · Taiwan (6) · Austria (5)
Geoffrey A Block, MD (4) · Julia B Lewis, MD (4) · David P Rosenbaum, PhD (3) · Geoff Block, MD (2) · Joseph Eustace, MB (2) · Wajeh Y Qunibi, M.D. (2) · Adrian Covic, Prof (1) · Alan H Lau, Pharm.D. (1) · Anders Alvestrand, MD PhD (1)
PMID 40576086, PMID 38323855, PMID 37853560, PMID 42664364, PMID 21854503, PMID 23797006, PMID 15930998, PMID 18385391, PMID 18423809, PMID 19211470, PMID 19539185, PMID 19776051, PMID 21324193, PMID 21426511, PMID 22994525, PMID 23369827, PMID 23670305, PMID 24840781, PMID 24968790, PMID 24975892, PMID 25079863, PMID 26184491, PMID 26239948, PMID 26670307, PMID 26843138, PMID 27007989, PMID 27479781, PMID 27528215, PMID 27647184, PMID 28398983, PMID 29064141, PMID 29617976, PMID 29989014, PMID 30352437, PMID 30459073, PMID 31302884, PMID 32651955, PMID 32706698, PMID 33766811, PMID 34003226, PMID 34462278, PMID 35187396, PMID 35236302, PMID 35239732, PMID 35372979, PMID 35810296, PMID 36472416, PMID 37473746, PMID 37598748, PMID 37910313
2008 (3), 2009 (1), R01DK142980 (1)